Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is an acute life-threatening disease characterized by the association of thrombocytopenia, microangiopathic hemolytic anemia, organ involvement and ADAMTS-13 protease deficiency [1]. The standard of care for iTTP has historically been based on therapeutic plasma exchange (TPE) and immune suppression. More recently, the treatment with caplacizumab has led to a significantly faster iTTP recovery. This is a nanobody that targets the interaction between platelet's glycoprotein 1b and the ultra-large A1 domain of von Willebrand factor (VWF).

Source: Thrombosis Research - June 15, 2023 Category: Hematology Authors: G. Caocci, O. Mulas, D. Mantovani, N. Bandinu, G. La Nasa Tags: Letter to the Editors-in-Chief Source Type: research